<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01587625</url>
  </required_header>
  <id_info>
    <org_study_id>Oxytocin high low dose</org_study_id>
    <nct_id>NCT01587625</nct_id>
  </id_info>
  <brief_title>High Dose Versus Low Dose Oxytocin for Augmentation of Delayed Labour</brief_title>
  <acronym>OxyHighLow</acronym>
  <official_title>High Dose Versus Low Dose Oxytocin for Augmentation of Delayed Labour</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Göteborg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vastra Gotaland Region</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Göteborg University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In a randomized control trial conducted in six study centers/labour wards in Sweden,&#xD;
      consenting nulliparous women in active phase of labour and with a defined delayed labour&#xD;
      progress will be randomized to receive a regimen of either high or low dose of oxytocin.&#xD;
      Primary outcome is caesarean delivery rate. Secondary outcomes are: Apgar score, need of&#xD;
      neonatal intensive care, hyper-stimulation of contractions, spontaneous vaginal birth rate,&#xD;
      length of labour, postpartum haemorrhage, sphincter lacerations, experienced labour pain,&#xD;
      epidural analgesia and the women´s childbirth experience one month postpartum (assessed with&#xD;
      Childbirth Experience Questionnaire). Study results will contribute to establish good&#xD;
      evidence-based routines regarding oxytocin treatment of delayed labour progress.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim is to compare starting dose and increment of amount of oxytocin for augmentation of&#xD;
      delayed labour to determine whether augmentation by high dose of oxytocin improves labour&#xD;
      outcomes compared with a low dose of oxytocin, without effecting neonatal outcomes or birth&#xD;
      experiences negatively.&#xD;
&#xD;
      Delay in labour, also described as poor progress, due to ineffective uterine contraction is a&#xD;
      major problem in modern obstetric care and one of the main reasons for the increased rate of&#xD;
      caesarean deliveries, in particular among nulliparous women. Infusion with synthetic oxytocin&#xD;
      is a commonly used treatment of hypotonic uterine contractions. Despite the widespread use of&#xD;
      oxytocin no consensus exists regarding the dosage of oxytocin, both starting dose and&#xD;
      increment of amount of oxytocin.&#xD;
&#xD;
      In a randomized control trial conducted in six study centers/labour wards in Sweden,&#xD;
      consenting nulliparous women in active phase of labour and with a defined delayed labour&#xD;
      progress will be randomized to receive a regimen of either high or low dose of oxytocin. The&#xD;
      expected outcome is a decreased caesarean section rate and increased rate of spontaneous&#xD;
      vaginal delivery for women with high dose of oxytocin for augmentation, without affecting&#xD;
      neonatal outcomes or childbirth experiences negatively.&#xD;
&#xD;
      Primary outcome is caesarean delivery rate. Secondary outcomes are Apgar score, need of&#xD;
      neonatal intensive care, hyper-stimulation of contractions, spontaneous vaginal birth rate,&#xD;
      length of labour, postpartum haemorrhage, sphincter lacerations, experienced labour pain,&#xD;
      epidural analgesia and the women´s childbirth experience one month postpartum (assessed with&#xD;
      Childbirth Experience Questionnaire). Based on a sample size calculation (α=0.05, β=0.80),&#xD;
      1045 women will be needed in each group. Analysis will be performed by the intention to&#xD;
      treat.&#xD;
&#xD;
      Study results will contribute to establish good evidence-based routines regarding oxytocin&#xD;
      treatment of delayed labour progress.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">October 8, 2016</completion_date>
  <primary_completion_date type="Actual">June 9, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Caesarean delivery rate</measure>
    <time_frame>At birth</time_frame>
    <description>data from clinical records</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Spontaneous vaginal birth rate</measure>
    <time_frame>At birth</time_frame>
    <description>data from clinical records</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of labour</measure>
    <time_frame>At birth</time_frame>
    <description>data from clinical records</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyper-stimulation of contractions</measure>
    <time_frame>At birth</time_frame>
    <description>data from clinical records</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postpartum haemorrhage</measure>
    <time_frame>Two hours postpartum</time_frame>
    <description>data from clinical records</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sphincter lacerations</measure>
    <time_frame>At birth</time_frame>
    <description>data from clinical records</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epidural analgesia</measure>
    <time_frame>At birth</time_frame>
    <description>data from clinical records</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Experienced labour pain</measure>
    <time_frame>Two hours postpartum</time_frame>
    <description>VAS 0-100 mm where 100 is highest pain level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Childbirth experience</measure>
    <time_frame>1 month postpartum</time_frame>
    <description>Childbirth Experience Questionnaire (CEQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apgar score</measure>
    <time_frame>Five minutes postpartum</time_frame>
    <description>data from clinical records</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal intensive care</measure>
    <time_frame>1 month postpartum</time_frame>
    <description>data from clinical records</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1376</enrollment>
  <condition>Birth; Delayed</condition>
  <arm_group>
    <arm_group_label>High dose of oxytocin infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxytocin: High dose infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose of oxytocin infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxytocin: Low dose infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <arm_group_label>High dose of oxytocin infusion</arm_group_label>
    <arm_group_label>Low dose of oxytocin infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy nulliparous women&#xD;
&#xD;
          -  singleton pregnancy&#xD;
&#xD;
          -  normal pregnancy&#xD;
&#xD;
          -  cephalic presentation&#xD;
&#xD;
          -  spontaneous onset of active labour&#xD;
&#xD;
          -  at term (37 - 42weeks gestation)&#xD;
&#xD;
          -  delay or arrest of active labour&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-Swedish speaking women&#xD;
&#xD;
          -  previous uterine surgery&#xD;
&#xD;
          -  intrauterine growth retardation &gt; - 22%&#xD;
&#xD;
          -  malpresentation at time of inclusion&#xD;
&#xD;
          -  intrapartal hemorrhage at time of inclusion&#xD;
&#xD;
          -  nonreassuring fetal-heart pattern at time of inclusion&#xD;
&#xD;
          -  meconium at time of inclusion&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Göteborg</city>
        <zip>41685</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NU Hospital Group</name>
      <address>
        <city>Trollhättan</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>April 19, 2012</study_first_submitted>
  <study_first_submitted_qc>April 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2012</study_first_posted>
  <last_update_submitted>March 1, 2019</last_update_submitted>
  <last_update_submitted_qc>March 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Delayed labour</keyword>
  <keyword>dystocia</keyword>
  <keyword>oxytocin augmentation</keyword>
  <keyword>primiparous women</keyword>
  <keyword>childbirth</keyword>
  <keyword>childbirth experience</keyword>
  <keyword>progress</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data for primary and secondary outcome measures from the two groups will be submitted to the Swedish National Data Service (Svensk Nationell Datatjänst, SND), a national authority responsible for administrating sharing of research data.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

